Full Press Release Details
Receives Reimbursement Approval for CGuard Embolic Prevention System from the French National Authority for Health
Aviv, Israel- October 13, 2021 - InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard Embolic Prevention
Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS
stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies
(CNEDIMTS) of the French National Authority for Health (HAS) regarding reimbursement in France, and the CGuard EPS is being added to
the list of reimbursed medical products (LPPR) effective October 25, 2021. This was the final step to full commercial launch of CGuard
EPS following CNEDIMTS' positive opinion for reimbursement received by the Company on May 11, 2021 for the treatment of symptomatic
and non-symptomatic lesions when surgery is not indicated.
CGuard EPS Self-Expanding Carotid Stent is the latest generation open-cell nitinol self-expanding stent with patented
MicroNet mesh technology designed to prevent the risk of early and late embolism.
milestone now provides physicians in France with the choice to use CGuard EPS in the treatment of carotid artery disease and stroke prevention.
We strive to improve the standard of care in the treatment of carotid artery disease, by moving away from surgical endarterectomy towards
less invasive options such as the CGuard EPS Carotid Stent System. We believe that the unique and proprietary design of our system, is
the most advanced and safest stent system on the market today," said Marvin Slosman, CEO of InspireMD.
Tommasoli, Senior VP Global Sales and Marketing commented, "We worked closely with HAS for over a year to gain reimbursement approval,
and its opinion validated the efficacy and safety of use of the CGuard EPS carotid stent based on our unmatched and expanding portfolio
of clinical evidence and the results of our extensive clinical research program. The expansion of CGuard into France represents further
progress in our efforts to grow the geographic reach of our commercial products as we continue to establish CGuard as the carotid device
of choice among physicians across the world that treat carotid disease."
CGuard carotid stent, is commercially established in 33 markets to date, adding France to our growing global expansion.
Identifier: NCT04900844
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing
outstanding acute results and durable, stroke-free, long-term outcomes.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. For example, the Company is using forward-looking statements when it discusses its belief that the unique and proprietary
design of its system is the most advanced and safe stent system on the market today and that the expansion of CGuard into France represents
further progress in its efforts to grow the geographic reach of its commercial products. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of
which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy
product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition
in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii)
our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement
by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property
protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both
the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will
need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency
exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political
and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization
of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including
the Company's Annual Report on Form 10-K and its filings with the SEC. Investors and security holders are urged to read these documents
free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Padala, Managing Director